21 - MANUFACTURE OF BASIC PHARMACEUTICAL PRODUCTS AND PHARMACEUTICAL PREPARATIONS Companies in Belgium
Approximately 1,642 real businesses classified under 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations in Belgium, with officer, shareholder and beneficial ownership records sourced directly from official government registries.
Approximately 1,642 real businesses classified under 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations operate in Belgium. Covers companies officially classified under NACEBEL 2008 code 21 (Manufacture of basic pharmaceutical products and pharmaceutical preparations), part of Belgium's NACEBEL 2008 classification of economic activities. This division is one of the sub-sectors making up the broader Manufacturing sector. Ownership, beneficial-ownership disclosure and company-registration rules for businesses under this specific activity code follow the same general framework that applies across Manufacturing in Belgium.
15 companies under this specific code are indexed on Zavia so far, part of a continually growing dataset.
Beneficial-ownership and registration rules for Manufacturing companies in Belgium follow the same national framework as every other sector there.
Full Belgium beneficial ownership overviewTop 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations Companies in Belgium
Live from the register. Every row opens the full record — officers, shareholders and resolved group structure.
Data Coverage
Record counts for NACE section C in Belgium, as of the last reconciliation.
Section C is 5% of the Belgium register by entity count and its 7th largest sector — see all sectors.
Analysis
What this data actually tells you
Manufacturing in Belgium is tracking a still-evolving EU compliance timeline rather than a settled national obligation. The Corporate Sustainability Due Diligence Directive’s Omnibus I amendments were published in the EU’s Official Journal on 26 February 2026 and entered into force 18 March 2026, moving CSDDD back into the national-transposition stage — member states, including Belgium, now have until 26 July 2028 to transpose it, with actual compliance required from in-scope companies by 26 July 2029.
The threshold itself is specific: due-diligence obligations apply to companies exceeding both 5,000 employees and €1.5 billion in net turnover, extending in certain cases to franchising arrangements and third-country companies meeting equivalent EU turnover thresholds. For verification, a Belgian manufacturer’s CSDDD exposure depends on checking these exact figures against its own group financials — a distinct, dated compliance question still years from taking effect, not a current obligation to assume is already in force.
Belgium Manufacturing, by the register
Charts render from live counts. Modules are suppressed where coverage is too thin to be meaningful.
Active vs. inactive
Section C entities currently on the register as active, vs. struck off or dormant.
Company size, by disclosed headcount
By number of employees on file, Section C, Belgium. 136 entities with no disclosed headcount are not counted in any band.
Who uses Belgium manufacturing ownership data
The three checks this sector's data is most often run for.
CSDDD Omnibus I timeline tracking
The EU’s Omnibus I amendments to the CSDDD entered into force 18 March 2026, pushing the national transposition deadline to 26 July 2028 and compliance for in-scope companies to 26 July 2029 — a real, dated timeline for Belgian manufacturers to track rather than a settled current obligation.
Scope threshold verification
CSDDD due-diligence obligations apply to companies exceeding both 5,000 employees and €1.5 billion net turnover, including certain franchise arrangements and third-country companies meeting specific EU turnover thresholds — a Belgian manufacturer’s in-scope status depends on checking these specific figures, not assuming from company size alone.
Lending and trade-credit exposure
Belgian manufacturing groups are frequently organised as a parent holding several operating subsidiaries; assessing exposure to one plant typically means understanding its place in that wider group rather than reading its own filing in isolation.
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring for Belgium companies — via API or a bulk data feed.
Frequently Asked Questions
How many companies are classified under 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations in Belgium?
Approximately 1,642 businesses are classified under 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations in Belgium.
What does NACEBEL 2008 code 21 cover?
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations is the official name for this activity under Belgium's NACEBEL 2008 classification of economic activities. It is a sub-category within the broader Manufacturing sector.
How is this different from the broader Manufacturing category?
Manufacturing is the top-level sector; NACEBEL 2008 code 21 identifies one specific activity within it, letting you narrow a search to exactly this business type rather than the whole sector.
What ownership information is available for these companies?
The same beneficial-ownership, shareholder and officer disclosure framework applies as for any other company in Belgium, regardless of its specific activity classification. See the individual company profile for the full ownership picture, or the Manufacturing sector overview for the general national framework.
All industries in Belgium
Every NACE section on this register, with live company counts.